Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (CTXR) reported its fiscal Q1 2026 results, revealing a period of commercial ramp-up supported by significant financing activities. The company generated revenue of $3.9 million for the quarter ending December 31, 2025, resulting in a gross profit of $3.2 million. However, substantial operating expenses, particularly in general and administrative costs ($5.7 million) and stock-based compensation ($4.3 million), drove an operating loss of $9.0 million and a net loss of $9.4 million. The net loss applicable to common stockholders stood at $8.2 million after accounting for non-controlling interests. On the balance sheet, the company maintains a robust asset base of $140.4 million, heavily weighted toward in-process research and development ($92.2 million) and inventory ($22.6 million). Cash flow from operations was negative $13.0 million, offset by $20.9 million in net proceeds from common stock offerings, resulting in a net increase in cash of $3.5 million. The company ended the period with $7.7 million in cash and cash equivalents. No prior period comparisons were available in the provided data to assess QoQ trends.

Key Takeaways